Health Alert:

Coronavirus Information: Vaccinations | Testing | Safety Policies & Visitor Guidelines | Appointments & Scheduling | FAQs

Did You Miss ASH 2018? Penn's Hematologic Malignancies CME Update

If you missed the American Society of Hematology annual meeting in December, a second opportunity to learn about research advances in the field is quickly approaching.

On February 1, the same distinguished team of Penn Medicine oncologic hematologic experts who presented at ASH 2018 will share their research updates at Penn’s annual CME event. Sponsored by the Abramson Cancer Center, the event invites healthcare professionals who treat patients with hematologic cancers to review the latest clinical research in the field’s most valued therapies.

Activity Director Edward Stadtmauer, MD

Activity Co-Director Edward A. Stadtmauer, MD

In past years, this event has been highly attended by hematologists, hematologist oncologists, medical oncologists and primary care physicians.

“The rapid progress of research in the hematologic malignancies — and its impact on evidence-based practices for patient care — has made it critically important for medical professionals to keep pace with the latest advances in the field,” said Activity Director Edward A. Stadtmauer, MD, Section Chief, Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant, Abramson Cancer Center. 

Event Agenda and Speakers

Formally called the Penn 2019 Updates in Care of the Hematologic Malignancies Patient CME event, the conference starts at 7:30 am and ends at 4:30 pm, with a robust agenda

Julianne Qualtieri, MD, Medical Director, Flow Cytometry Lab, Division of Hematopathology at the Perelman School of Medicine, will deliver the keynote presentation on optimizing flow cytometry to diagnose and manage blood cancers. Penn has the largest academic flow cytometry lab in the country.

Other highlights include:

  • Review of new data for patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL);  
  • A review of early clinical data on AMG 420, an anti-BCMA Bispecific T-cell engager, in patients with r/r multiple myeloma, as well as longer-term analyses of CAR-T therapy in two key clinical trials; and 
  • Two panel discussions, one led by Dr. Stadtmauer

Fellow activity co-directors are David L. Porter, MD, the Jodi Fisher Horowitz Professor of Leukemia Care Excellence, Division of Hematology Oncology, Director, Cell Therapy and Transplantation; and Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor of Chronic Lymphocytic Leukemia and Lymphoma, Division of Hematology Oncology, Director, Lymphoma Program and Lymphoma Translational Research.


This maximum of 7.5 AMA PRA Category 1 Credits™ provides significant opportunity for attendees to discuss the implementation of new standards of patient care, recent research and concepts with expert faculty and other attendees. Participants will leave with up-to-date, practical information that can be applied immediately in clinic.

For questions or additional information, please email Barbara Lopez at

Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education and the American Nurses Credentialing Center.

About this Blog

The Penn Physician Blog is a resource for health care professionals featuring Penn Medicine physicians and their research, innovations, programs and events. 

Date Archives

Share This Page: